<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27316678</article-id><article-id pub-id-type="pmc">4912827</article-id><article-id pub-id-type="publisher-id">625</article-id><article-id pub-id-type="doi">10.1186/s12974-016-0625-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Allison</surname><given-names>David J.</given-names></name><address><phone>289 668 0656</phone><email>dallison@brocku.ca</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Aysha</given-names></name><address><email>aysha.thomas@brocku.ca</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Beaudry</surname><given-names>Kayleigh</given-names></name><address><email>kayleigh.beaudry@brocku.ca</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ditor</surname><given-names>David S.</given-names></name><address><email>dditor@brocku.ca</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Kinesiology, Brock University, St Catharines, Ontario L2S 3A1 Canada </aff><aff id="Aff2"><label/>Brock-Niagara Centre for Health and Well-being, St Catharines, Ontario L2T 1W4 Canada </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>13</volume><elocation-id>152</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI).</p></sec><sec><title>Methods</title><p>This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4.</p></sec><sec><title>Results</title><p>A significant group&#x02009;&#x000d7;&#x02009;time interaction was found for sensory pain scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). A Mann-Whitney test revealed that the change scores (3-month baseline) were significantly different between groups for IFN-y (<italic>U</italic>&#x02009;=&#x02009;13.0, <italic>p</italic>&#x02009;=&#x02009;0.01), IL-1&#x003b2; (<italic>U</italic>&#x02009;=&#x02009;14.0, <italic>p</italic>&#x02009;=&#x02009;0.01), and IL-2 (<italic>U</italic>&#x02009;=&#x02009;12.0, <italic>p</italic>&#x02009;=&#x02009;0.01). A Friedman test revealed the treatment group had a significant reduction in IFN-y (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;8.67, <italic>p</italic>&#x02009;=&#x02009;0.01), IL-1&#x003b2; (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;17.78, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), IL-6 (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;6.17, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), while the control group showed no significant change in any inflammatory mediator. A stepwise backward elimination multiple regression analysis showed that the change in sensory neuropathic pain was a function of the change in the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (<italic>R</italic>&#x02009;=&#x02009;0.689, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.474).</p></sec><sec><title>Conclusions</title><p>Overall, the results of the study demonstrate the efficacy of targeting inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism relating to the reduction in proinflammatory cytokines and PGE2.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02099890">NCT02099890</ext-link></p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12974-016-0625-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neuropathic pain</kwd><kwd>Spinal cord injury</kwd><kwd>Inflammation</kwd><kwd>Anti-inflammatory diet</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000049</institution-id><institution>Ontario Neurotrauma Foundation</institution></institution-wrap></funding-source><award-id>2011-ONF-RHI-MT-894</award-id><principal-award-recipient><name><surname>Ditor</surname><given-names>David S.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Damage to the nervous system may result in persistent or permanent changes to nociceptive thresholds resulting in a unique pain state characterized by allodynia and/or hyperalgesia [<xref ref-type="bibr" rid="CR1">1</xref>]. This form of pain, known as neuropathic pain, effects an estimated 29&#x02013;75&#x000a0;% of the spinal cord injured (SCI) population [<xref ref-type="bibr" rid="CR2">2</xref>]. Such a condition can be severely debilitating following SCI and may contribute to inactivity and related metabolic conditions, as well as behavioral disorders such depression, anxiety, and insomnia [<xref ref-type="bibr" rid="CR3">3</xref>]. Neuropathic pain is notoriously difficult to treat, and no current treatment has been consistently proven as universally effective, predictable, and safe for long-term use [<xref ref-type="bibr" rid="CR4">4</xref>]. Based on the widespread potential to impact quality of life, it is imperative to gain a better understanding of the underlying mechanisms of neuropathic pain and explore novel treatments.</p><p>Traditionally, neuropathic pain has been viewed as an etiology stemming solely from structural damage to the neuron itself. However, it is now well-established that the environment with which the nociceptor interacts is also an important factor [<xref ref-type="bibr" rid="CR5">5</xref>]. A number of inflammatory mediators are known to reduce the nociceptive threshold, resulting in symptoms of hyperalgesia [<xref ref-type="bibr" rid="CR5">5</xref>]. Proinflammatory cytokines such as IL-1&#x003b2; (interleukin-1 beta), IFN-y (interferon gamma), IL-6, and TNF-&#x003b1; (tumor necrosis factor-alpha) have been proposed to induce algesic effects by both direct [<xref ref-type="bibr" rid="CR6">6</xref>] and indirect [<xref ref-type="bibr" rid="CR7">7</xref>] (prostaglandin-dependent) influences. The inflammatory etiology of neuropathic pain is further supported based on evidence that analgesic effects have been produced following the reduction of proinflammatory cytokine concentrations. This has been demonstrated in animal models following the administration of antibodies against TNF-&#x003b1; [<xref ref-type="bibr" rid="CR8">8</xref>] as well as in transgenic animal models with impaired IL-1&#x003b2; production [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Pharmacological treatment strategies are currently the most heavily relied upon form of neuropathic pain management. Studies have, however, shown mixed results concerning the efficacy, universality, and associated side effects of treatments such as tricyclic antidepressants, SSRI&#x02019;s, cannabinoids, anticonvulsants, and opioids [<xref ref-type="bibr" rid="CR4">4</xref>]. This inconsistency across studies may be due, in part, to variability in protocols (e.g., duration, dosage) but may also relate to the varied etiological basis across different participants. A better understanding of the various mechanisms at play and a more advanced mechanism-based classification system will be critical to enhance the specificity and efficacy of current pharmacological treatments. This may contribute to the development of pharmacological treatments which target the underlying mechanisms responsible for neuropathic pain as opposed to focusing solely on symptom relief.</p><p>An additive to traditional pharmaceutical treatments may be the implementation of anti-inflammatory interventions. Such strategies would target the common inflammatory mechanisms which underlie various etiologies thereby having the potential to provide a more widely applicable treatment option. Further, if such strategies prove effective, it may be possible to produce such anti-inflammatory effects via simple lifestyle alterations without the use of pharmaceuticals. This may help to reduce the reliance on traditional pharmaceuticals thereby helping to avoid associated side effects. Appropriate dietary alterations including foods and supplements with established anti-inflammatory benefits have been shown to effectively reduce inflammation via a number of mechanisms ranging from altered gene transcription, changes in cell membrane composition, and improved enzyme regulation, as well as improvements in metabolic heath and body composition [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Dietary needs, including nutrient requirements and caloric intake, change drastically following SCI and are often not adequately met. Diet is, therefore, likely a substantial contributing factor to the chronic inflammation typically observed following SCI [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. A dietary intervention consisting of foods and supplements with established anti-inflammatory benefits was therefore utilized in the current study with the intention of reducing inflammation for the purpose of studying the effect on neuropathic pain. It was hypothesized that by reducing chronically elevated levels of inflammatory mediators, corresponding reductions in neuropathic pain would be achieved.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p>This study was performed as a component of a larger clinical trial (clinicaltrials.gov identifier: NCT02099890) which included the examination of depression [<xref ref-type="bibr" rid="CR14">14</xref>], cognitive impairment, and somatic nerve function. Data pertaining to the change in inflammatory mediators has been previously published [<xref ref-type="bibr" rid="CR14">14</xref>]. The study was a randomized, parallel-group clinical trial. Participant recruitment occurred between September and November 2014. The study intervention was 12&#x000a0;weeks and included testing at baseline, 1&#x000a0;month, and 3&#x000a0;months. Participants with various levels and severities of SCI were recruited for participation in the study. Additional inclusion criteria included (1) over the age of 18, (2) SCI of any level or severity (American Spinal Injury Association A-D), (3) at least 2&#x000a0;years post-injury. Exclusion criteria included (1) any contraindications to supplements provided in the study, (2) unstable dosage of any pain medications, (3) unstable medical condition within 2&#x000a0;weeks prior to intervention, (4) pregnancy, and (5) breastfeeding. Participant characteristics are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Twenty individuals (10 males, 10 females; age 48.7&#x02009;&#x000b1;&#x02009;13.9&#x000a0;years) with chronic (4&#x02013;37&#x000a0;years post-injury) SCI (C2-L4; ASIA Impairment Scale (AIS) A-D) were recruited for participation in the study. Twelve participants were randomly allocated to the treatment group and were placed on the 12-week anti-inflammatory diet intervention, while eight were allocated to the control group and received no intervention. This group allocation was selected in order to protect against potential dropouts. Three participants (two from the treatment group and one from the control group) were using medications which could influence pain. These medications included oxycodone and baclofen (used by the two participants of the treatment group) and gabapentin (used by the participant of the control group). Dosages of these medications were, however, maintained throughout the duration of the study. Informed consent was obtained from all participants. The study was registered as a clinical trial (clinicaltrials.gov identifier: NCT02099890) and received ethical approval from the Brock University Research Ethics Board as well as the Natural Health Products Directorate of Canada. All data was collected on-site at Brock University and the Brock-Niagara center for health and well-being.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participant characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Participant</th><th>Sex</th><th>Age</th><th>AIS score</th><th>Level</th><th>Time since injury (years)</th></tr></thead><tbody><tr><td colspan="6">Treatment</td></tr><tr><td>&#x02003;1</td><td>F</td><td>44</td><td>D</td><td>C5</td><td>10</td></tr><tr><td>&#x02003;2</td><td>M</td><td>58</td><td>B</td><td>T10</td><td>4</td></tr><tr><td>&#x02003;3</td><td>F</td><td>62</td><td>D</td><td>L3</td><td>4</td></tr><tr><td>&#x02003;4</td><td>F</td><td>37</td><td>A</td><td>T3</td><td>19</td></tr><tr><td>&#x02003;5</td><td>M</td><td>22</td><td>A</td><td>C7</td><td>5</td></tr><tr><td>&#x02003;6</td><td>M</td><td>67</td><td>C</td><td>C2</td><td>4</td></tr><tr><td>&#x02003;7</td><td>M</td><td>66</td><td>D</td><td>C5</td><td>6</td></tr><tr><td>&#x02003;8</td><td>F</td><td>44</td><td>A</td><td>C7</td><td>9</td></tr><tr><td>&#x02003;9</td><td>F</td><td>65</td><td>D</td><td>T6</td><td>4</td></tr><tr><td>&#x02003;10</td><td>F</td><td>64</td><td>D</td><td>C3</td><td>37</td></tr><tr><td>&#x02003;11</td><td>M</td><td>45</td><td>A</td><td>T6</td><td>28</td></tr><tr><td>&#x02003;12</td><td>M</td><td>37</td><td>C</td><td>C4</td><td>23</td></tr><tr><td colspan="6">Control</td></tr><tr><td>&#x02003;13</td><td>F</td><td>30</td><td>B</td><td>C5</td><td>6</td></tr><tr><td>&#x02003;14</td><td>F</td><td>63</td><td>D</td><td>L4</td><td>2</td></tr><tr><td>&#x02003;15</td><td>M</td><td>42</td><td>A</td><td>C5</td><td>6</td></tr><tr><td>&#x02003;16</td><td>F</td><td>58</td><td>D</td><td>C5</td><td>33</td></tr><tr><td>&#x02003;17</td><td>M</td><td>59</td><td>D</td><td>T4</td><td>4</td></tr><tr><td>&#x02003;18</td><td>F</td><td>33</td><td>A</td><td>T1</td><td>17</td></tr><tr><td>&#x02003;19</td><td>M</td><td>41</td><td>C</td><td>C4</td><td>22</td></tr><tr><td>&#x02003;20</td><td>M</td><td>36</td><td>A</td><td>C5</td><td>19</td></tr></tbody></table><table-wrap-foot><p>
<italic>AIS</italic> ASIA (American Spinal Injury Association) Impairment Scale</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Randomization</title><p>Randomization was computer generated by the primary investigator and stratified by participant gender and age using permuted blocks of 2 (male/female) and block of 3 (&#x0003c;40, 40&#x02013;60, &#x0003e;60&#x000a0;years). Randomization was 3:2 to either the anti-inflammatory diet vs control.</p></sec><sec id="Sec5"><title>Anti-inflammatory diet intervention</title><p>The anti-inflammatory diet intervention focused on the elimination of common food intolerances and inflammation-inducing foods, as well as the introduction of foods and supplements with established anti-inflammatory properties. Examples of foods removed from the diet included those with high glycemic indices (such as refined wheat products and refined sugars), common intolerances such as cow&#x02019;s milk, and foods which negatively influence cardiovascular health such as hydrogenated oils. Participants also consumed daily supplements with established anti-inflammatory benefits. Omega-3 (Now Ultra omega-3) was taken in softgel form, containing 500&#x000a0;mg EPA and 250&#x000a0;mg DHA, at a dosage of 3 per day. Chlorella (Now chlorella) was taken in pill form, containing 1000&#x000a0;mg, at a dosage of 6 per day. Antioxidants (CanPrev antioxidant network) were taken in pill form, containing 100&#x000a0;mg coenzyme Q10, 200&#x000a0;mg <italic>n</italic>-acetyl-cysteine, 150&#x000a0;mg mixed tocopherols, 100&#x000a0;mg DL alpha lipoic acid, 60&#x000a0;mg green tea extract, 5.5&#x000a0;mg zinc, and 100&#x000a0;&#x003bc;g selenium, at dosage of 2 per day. Curcumin (AOR Inflanox) was taken in pill form, containing 400&#x000a0;mg, at a dosage of 3 per day. A vegetable-based protein powder (Progressive Vegessential) containing 27&#x000a0;g of protein was taken at a dosage of one scoop each morning.</p><p>Both the treatment group and control group were asked to complete a detailed diet record for 7&#x000a0;days at baseline, as well as 3&#x000a0;days at 1-month, 2-month, and 3-months in order to establish baseline eating habits and assess compliance throughout the intervention. Food intake was assessed using The Food Processor (ESHA Inc. 2014, version 10.14.2, Salem, OR). Compliance to the specific anti-inflammatory diet was also assessed by a detailed analysis of all diet records. Each food item was categorized as either a &#x0201c;food to consume,&#x0201d; a &#x0201c;food to avoid,&#x0201d; or a &#x0201c;neutral food&#x0201d; based on the parameter of the diet participants who were instructed to follow. Food was also categorized into servings in accordance with Canada&#x02019;s Food Guide. Therefore, compliance score was based on standard servings of foods: subjects were instructed to eat vs. foods they were instructed to avoid. To account for differences in total energy intake, compliance scores were expressed as a ratio of the servings of foods to consume over the total servings of food (avoid&#x02009;+&#x02009;consume) multiplied by 100. The percent compliance was then generated. The treatment group then underwent an information seminar which explained the diet program followed by a one-on-one consultation with nutritionists whereby their diet records were reviewed in detail and necessary changes were discussed. Participants received information regarding foods to eat and avoid, a supplement intake schedule, and list of approved recipes. Participants in the treatment group received support via weekly phone calls from members of our research team as well as an online support group whereby participants could share recipes and experiences with one another. Participants in the control group were asked to maintain their current diets throughout the duration of the study.</p></sec><sec id="Sec6"><title>Measurement of serum inflammatory markers</title><p>Blood draws (20&#x000a0;ml) were taken from the antecubital vein of each participant at 1&#x000a0;pm at each of the three testing sessions (baseline, 1&#x000a0;month, and 3&#x000a0;months). Following extraction, the whole blood was allowed to clot for 30&#x000a0;min followed by centrifugation at 1000&#x000d7;<italic>g</italic> for 15&#x000a0;min. Serum was extracted and immediately stored at &#x02212;80&#x000a0;&#x000b0;C until later analysis. Inflammatory mediators of interest included the proinflammatory cytokines IL-2, IL-1B, IL-6, TNF-alpha, IFN-y, acute phase protein CRP (C-reactive protein), eicosanoids PGE2 (prostaglandin E2), and LTB4 (leukotriene B4), as well as the anti-inflammatory cytokines IL-4, IL-10, and IL-1RA. Both pro- and anti-inflammatory cytokines were assessed due to findings that painful neuropathy has been shown to be associated with elevated levels of proinflammatory mediators and reduced levels of anti-inflammatory mediators while non-painful neuropathy has shown the opposite [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Improvements in neuropathic pain may therefore relate to reductions in proinflammatory mediators and/or elevations in anti-inflammatory mediators. Analysis of pro- and anti-inflammatory cytokines was performed in triplicate via the Magpix Multiplex system and analyzed using Luminex software. CRP, PGE2, and LTB4 were analyzed in triplicate and quantified via enzyme-linked immunosorbent assay (R&#x00026;D systems, Minneapolis, USA).</p></sec><sec id="Sec7"><title>Assessment of neuropathic pain</title><p>Participants were asked to complete the Neuropathic Pain Questionnaire (NPQ) at each of the three testing sessions, as a means of assessing self-reported neuropathic pain. The questionnaire consisted of 32 items pertaining to three unique categories including sensory items, affective items, and sensitivity items. Sensory items were those related to the specific type and severity of pain felt (e.g., degree of burning, stabbing, throbbing), affective items referred to those related to how the pain affected the participant in daily life (e.g., how irritating is your usual pain?) and sensitivity items related to how various stimuli may act to increase pain (e.g., increased pain due to heat). Participants were asked to rate their pain numerically on a scale from 0&#x02013;100 whereby 0 indicated the complete absence of pain and 100 indicated the worst pain imaginable. Scores from each of the three categories were averaged for use in statistical analysis.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Two-way (group&#x02009;&#x000d7;&#x02009;time) repeated measures ANOVA were performed to investigate possible changes in pain scores related to sensory and affective pain across three testing sessions (baseline, 1&#x000a0;month, 3&#x000a0;months). Two-way repeated measures ANOVA were also performed for the proinflammatory cytokine TNF-&#x003b1; and the eicosanoid PGE2. As the remaining inflammatory mediators as well as sensitivity pain scores were not normally distributed, non-parametric analyses were performed. A Friedman&#x02019;s test of differences among repeated measures (baseline, 1&#x000a0;month, and 3&#x000a0;months) for the treatment group and control was performed. If the Friedman&#x02019;s test resulted in a significant value, a Wilcoxon signed-rank test was then performed to provide specific information regarding which time points were significantly different from one another. Finally, A Mann-Whitney test was performed on change scores (3 months&#x02009;&#x02212;&#x02009;baseline) between groups to establish if the change experienced significantly differed between groups. These data are expressed as means&#x02009;&#x000b1;&#x02009;standard deviations. Correlations between changes in inflammatory mediators and neuropathic pain scores were assessed by means of Pearson&#x02019;s r correlation. Statistical significance was set at <italic>p</italic>&#x02009;&#x02264;&#x02009;0.05 for all tests. The proportional contribution of the change in each inflammatory mediator to the change in pain score was evaluated using a stepwise backward elimination multiple regression. Levels of F to enter and F to remove were set to correspond to p-levels of 0.05 and 0.10, respectively. In order to control for the potential influence of depression on scores of neuropathic pain, an additional multiple regression was performed while controlling for CES-D (center for epidemiological studies depression scale) scores of depression. Details of the CES-D have been previously described [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><p>All participants from both the treatment and control group completed the entire 3-month duration of the study and were included in the analysis. No adverse events were reported. The participants&#x02019; overall compliance to the diet was assessed based on the average of the three diet records during the study (1&#x000a0;month, 2&#x000a0;months, and 3&#x000a0;months). One participant completed all three testing sessions but failed to produce the 2-month and the 3-month diet record. This participant had a dietary compliance over the first month of 92&#x000a0;%. All other participants completed each of the required diet records, and overall compliance ranged from 70 to 100&#x000a0;%, with a mean compliance of 89&#x000a0;%. A detailed analysis regarding specific diet adherence data will be presented elsewhere.</p><sec id="Sec10"><title>Change in pain scores</title><p>Changes in sensory, affective, and sensitivity pain scores are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. There was a significant group&#x02009;&#x000d7;&#x02009;time interaction for the sensory component of the self-reported neuropathic pain scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; Cohen&#x02019;s <italic>d</italic>&#x02009;=&#x02009;1.29). Post hoc analysis showed a significant reduction in sensory scores in the treatment group from both baseline to 1&#x000a0;month, as well as baseline to 3&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.00 and <italic>p</italic>&#x02009;=&#x02009;0.01, respectively). This included reductions of greater than 30&#x000a0;% for six participants and a reduction between 20 and 30&#x000a0;% for another three participants. Post hoc analysis showed a significant increase in sensory scores in the control group from baseline to 1&#x000a0;month (<italic>p</italic>&#x02009;=&#x02009;0.04) but no significant change from baseline to 3&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.210). No significant group&#x02009;&#x000d7;&#x02009;interaction was found for the affective component of the self-reported neuropathic pain scores (<italic>p</italic>&#x02009;=&#x02009;0.17; Cohen&#x02019;s <italic>d</italic>&#x02009;=&#x02009;0.63). Of note, the change in affective neuropathic pain scores were significantly correlated to the previously reported scores related to changes in mood in this population [<xref ref-type="bibr" rid="CR14">14</xref>]. In regard to the non-parametric analysis of sensitivity scores, the Mann-Whitney test indicated that change scores of sensitivity pain were not significantly different between the treatment group and control group (<italic>U</italic>&#x02009;=&#x02009;36.0, <italic>p</italic>&#x02009;=&#x02009;0.35). The Friedman test showed that there was no significant change in sensitivity pain scores for either the treatment group (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;3.38, <italic>p</italic>&#x02009;=&#x02009;0.19) or control group (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;0.09, <italic>p</italic>&#x02009;=&#x02009;0.96) across testing sessions.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Changes in neuropathic pain questionnaire scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Treatment (<italic>n</italic>&#x02009;=&#x02009;12)</th><th colspan="3">Control (<italic>n</italic>&#x02009;=&#x02009;8)</th><th>Two-way ANOVA (<italic>p</italic> value)</th><th>Mann-Whitney (<italic>p</italic> value)</th><th>Friedman [Treat.] (<italic>p</italic> value)</th></tr><tr><th/><th>Baseline</th><th>1&#x000a0;month</th><th>3&#x000a0;months</th><th>Baseline</th><th>1&#x000a0;month</th><th>3&#x000a0;months</th><th/><th/><th/></tr></thead><tbody><tr><td>Sensory score</td><td>32.8&#x02009;&#x000b1;&#x02009;23.4</td><td>23.4&#x02009;&#x000b1;&#x02009;20.2**</td><td>19.8&#x02009;&#x000b1;&#x02009;15.8**</td><td>18.1&#x02009;&#x000b1;&#x02009;17.2</td><td>25.2&#x02009;&#x000b1;&#x02009;22.2*</td><td>21.3&#x02009;&#x000b1;&#x02009;20.1</td><td>&#x0003c;0.01</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Affective score</td><td>34.7&#x02009;&#x000b1;&#x02009;28.6</td><td>24.3&#x02009;&#x000b1;&#x02009;21.9</td><td>21.2&#x02009;&#x000b1;&#x02009;19.0</td><td>27.5&#x02009;&#x000b1;&#x02009;24.4</td><td>20.1&#x02009;&#x000b1;&#x02009;23.0</td><td>23.7&#x02009;&#x000b1;&#x02009;25.3</td><td>0.18</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Sensitivity score</td><td>26.8&#x02009;&#x000b1;&#x02009;26.1</td><td>22.6&#x02009;&#x000b1;&#x02009;21.2</td><td>22.6&#x02009;&#x000b1;&#x02009;20.7</td><td>29.7&#x02009;&#x000b1;&#x02009;32.9</td><td>33.7&#x02009;&#x000b1;&#x02009;26.9</td><td>32.6&#x02009;&#x000b1;&#x02009;26.3</td><td>&#x02013;</td><td>0.35</td><td>0.19</td></tr></tbody></table><table-wrap-foot><p>All results are shown as mean&#x02009;&#x000b1;&#x02009;SD. <italic>p</italic> values correspond to group&#x02009;&#x000d7;&#x02009;time interactions, Mann-Whitney change scores, and Friedman scores for treatment group, respectively (Friedman scores for control group not shown)</p><p>*Significantly different from baseline with <italic>p</italic> value &#x0003c;0.05</p><p>**Significantly different from baseline with <italic>p</italic> value &#x0003c;0.01</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Change in inflammatory mediators</title><p>Changes in serum levels of inflammatory mediators are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. When considering a proinflammatory composite score (average of IL-2, IL-6, IL-1&#x003b2;, TNF-&#x003b1;, and IFN-y), the Mann-Whitney test indicated that the change scores (3&#x000a0;months&#x02009;&#x02212;&#x02009;baseline) were significantly different between the treatment group and the control group (<italic>U</italic>&#x02009;=&#x02009;13.0, <italic>p</italic>&#x02009;=&#x02009;0.01). The Friedman test showed that there was a statistically significant reduction in the proinflammatory composite scores in the treatment group (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;6.50, <italic>p</italic>&#x02009;=&#x02009;0.04), but no significant change in the control group (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;5.25, <italic>p</italic>&#x02009;=&#x02009;0.07). Post hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions in the treatment group from both baseline to 1&#x000a0;month and baseline to 3&#x000a0;months (<italic>z</italic>&#x02009;=&#x02009;&#x02212;2.197, <italic>p</italic>&#x02009;=&#x02009;0.03; <italic>z</italic>&#x02009;=&#x02009;&#x02212;2.275, <italic>p</italic>&#x02009;=&#x02009;0.02 respectively). When analyzing each cytokine separately, the Mann-Whitney test indicated that the change scores (3&#x000a0;months&#x02009;&#x02212;&#x02009;baseline) were significantly different between the treatment group and the control group for IFN-y (<italic>U</italic>&#x02009;=&#x02009;13.0, <italic>p</italic>&#x02009;=&#x02009;0.01.), IL-1&#x003b2; (<italic>U</italic>&#x02009;=&#x02009;14.0, <italic>p</italic>&#x02009;=&#x02009;0.01), and IL-2 (<italic>U</italic>&#x02009;=&#x02009;12.0, <italic>p</italic>&#x02009;=&#x02009;0.01) and showed a trend for CRP (<italic>U</italic>&#x02009;=&#x02009;27.0, <italic>p</italic>&#x02009;=&#x02009;0.10). The Friedman test showed that in the treatment group, there was a statistically significant reduction in IFN-y (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;8.67, <italic>p</italic>&#x02009;=&#x02009;0.01), IL-1&#x003b2; (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;17.78, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), IL-6 (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;6.17, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), and a trend for CRP (<italic>x</italic><sup>2</sup>&#x02009;=&#x02009;4.5, <italic>p</italic>&#x02009;=&#x02009;0.10). The Friedman test showed no statistically significant reductions for any inflammatory mediator in the control group. Post hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions in the treatment group for IFN-y from baseline to 1&#x000a0;month and baseline to 3&#x000a0;months (<italic>z</italic>&#x02009;=&#x02009;&#x02212;2.275, <italic>p</italic>&#x02009;=&#x02009;0.02; <italic>z</italic>&#x02009;=&#x02009;&#x02212;2.510, <italic>p</italic>&#x02009;=&#x02009;0.01, respectively), as well as significant reductions in the treatment group for IL-1&#x003b2; from baseline to 1&#x000a0;month and baseline to 3&#x000a0;months (<italic>z</italic>&#x02009;=&#x02009;&#x02212;3.059, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; <italic>z</italic>&#x02009;=&#x02009;&#x02212;2.934, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively), and a significant reduction in the treatment group for IL-6 from baseline to 1&#x000a0;month, and a trend from baseline to 3&#x000a0;months (<italic>z</italic>&#x02009;=&#x02009;&#x02212;2.275, <italic>p</italic>&#x02009;=&#x02009;0.02; <italic>z</italic>&#x02009;=&#x02009;&#x02212;1.726, <italic>p</italic>&#x02009;=&#x02009;0.08, respectively). Two-way repeated measures ANOVA were performed for the normally distributed mediator&#x02019;s TNF-&#x003b1; and PGE2 and showed trends towards group&#x02009;&#x000d7;&#x02009;time interactions (<italic>p</italic>&#x02009;=&#x02009;0.10; <italic>p</italic>&#x02009;=&#x02009;0.07 respectively).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Changes in inflammatory mediators</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Treatment (<italic>n</italic>&#x02009;=&#x02009;12)</th><th colspan="3">Control (<italic>n</italic>&#x02009;=&#x02009;8)</th><th>Two-way ANOVA (<italic>p</italic> value)</th><th>Mann-Whitney (<italic>p</italic> value)</th><th>Friedman [Treat.] (<italic>p</italic> value)</th></tr><tr><th/><th>Baseline</th><th>1&#x000a0;month</th><th>3&#x000a0;months</th><th>Baseline</th><th>1&#x000a0;month</th><th>3&#x000a0;months</th><th/><th/><th/></tr></thead><tbody><tr><td>Proinflammatory composite (pg/ml)</td><td>20.3&#x02009;&#x000b1;&#x02009;34.5</td><td>13.1&#x02009;&#x000b1;&#x02009;23.6*</td><td>14.6&#x02009;&#x000b1;&#x02009;25.2*</td><td>9.8&#x02009;&#x000b1;&#x02009;11.6</td><td>15.4&#x02009;&#x000b1;&#x02009;22.3</td><td>15.7&#x02009;&#x000b1;&#x02009;25.3</td><td>&#x02013;</td><td>&#x0003c;0.01</td><td>0.04</td></tr><tr><td>CRP (ng/ml)</td><td>4474.7&#x02009;&#x000b1;&#x02009;3578.9</td><td>3822.6&#x02009;&#x000b1;&#x02009;3749.4</td><td>2865.0&#x02009;&#x000b1;&#x02009;2684.9</td><td>2388.1&#x02009;&#x000b1;&#x02009;2928.1</td><td>3074.0&#x02009;&#x000b1;&#x02009;3026.4</td><td>2458.8&#x02009;&#x000b1;&#x02009;3678.9</td><td>&#x02013;</td><td>0.10</td><td>0.10</td></tr><tr><td>IL-2 (pg/ml)</td><td>21.3&#x02009;&#x000b1;&#x02009;51.2</td><td>15.1&#x02009;&#x000b1;&#x02009;41.7</td><td>17.2&#x02009;&#x000b1;&#x02009;42.1</td><td>1.7&#x02009;&#x000b1;&#x02009;3.4</td><td>2.9&#x02009;&#x000b1;&#x02009;3.6</td><td>2.3&#x02009;&#x000b1;&#x02009;3.3</td><td>&#x02013;</td><td>&#x0003c;0.01</td><td>0.23</td></tr><tr><td>IL-6 (pg/ml)</td><td>13.9&#x02009;&#x000b1;&#x02009;28.2</td><td>9.2&#x02009;&#x000b1;&#x02009;21.3*</td><td>9.5&#x02009;&#x000b1;&#x02009;19.3</td><td>9.0&#x02009;&#x000b1;&#x02009;10.5</td><td>13.8&#x02009;&#x000b1;&#x02009;21.2</td><td>13.5&#x02009;&#x000b1;&#x02009;21.9</td><td>&#x02013;</td><td>0.13</td><td>0.049</td></tr><tr><td>IL-1B (pg/ml)</td><td>0.9&#x02009;&#x000b1;&#x02009;1.1</td><td>0.3&#x02009;&#x000b1;&#x02009;0.3**</td><td>0.3&#x02009;&#x000b1;&#x02009;0.2**</td><td>0.3&#x02009;&#x000b1;&#x02009;0.3</td><td>0.4&#x02009;&#x000b1;&#x02009;0.5</td><td>0.3&#x02009;&#x000b1;&#x02009;0.2</td><td>&#x02013;</td><td>&#x0003c;0.01</td><td>&#x0003c;0.01</td></tr><tr><td>TNF-&#x003b1; (pg/ml)</td><td>12.5&#x02009;&#x000b1;&#x02009;3.6</td><td>11.8&#x02009;&#x000b1;&#x02009;5.5</td><td>11.2&#x02009;&#x000b1;&#x02009;4.1</td><td>9.8&#x02009;&#x000b1;&#x02009;3.9</td><td>11.3&#x02009;&#x000b1;&#x02009;6.7</td><td>12.9&#x02009;&#x000b1;&#x02009;10.3</td><td>0.10</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>IFN-y (pg/ml)</td><td>52.9&#x02009;&#x000b1;&#x02009;94.0</td><td>31.9&#x02009;&#x000b1;&#x02009;57.5*</td><td>35.0&#x02009;&#x000b1;&#x02009;68.4*</td><td>28.1&#x02009;&#x000b1;&#x02009;46.8</td><td>48.8&#x02009;&#x000b1;&#x02009;84.6</td><td>49.6&#x02009;&#x000b1;&#x02009;95.3</td><td>&#x02013;</td><td>&#x0003c;0.01</td><td>0.01</td></tr><tr><td>Anti-inflammatory Composite (pg/ml)</td><td>15.7&#x02009;&#x000b1;&#x02009;13.7</td><td>17.2&#x02009;&#x000b1;&#x02009;15.4</td><td>17.3&#x02009;&#x000b1;&#x02009;19.1</td><td>28.8&#x02009;&#x000b1;&#x02009;28.3</td><td>40.1&#x02009;&#x000b1;&#x02009;44.9</td><td>36.3&#x02009;&#x000b1;&#x02009;39.5</td><td>&#x02013;</td><td>0.32</td><td>1.0</td></tr><tr><td>IL-4 (pg/ml)</td><td>7.5&#x02009;&#x000b1;&#x02009;20.8</td><td>12.4&#x02009;&#x000b1;&#x02009;23.9</td><td>16.2&#x02009;&#x000b1;&#x02009;38.4</td><td>19.8&#x02009;&#x000b1;&#x02009;37.2</td><td>37.4&#x02009;&#x000b1;&#x02009;83.8</td><td>23.8&#x02009;&#x000b1;&#x02009;46.3</td><td>&#x02013;</td><td>0.54</td><td>0.63</td></tr><tr><td>IL-10 (pg/ml)</td><td>6.5&#x02009;&#x000b1;&#x02009;12.9</td><td>11.2&#x02009;&#x000b1;&#x02009;29.7</td><td>9.3&#x02009;&#x000b1;&#x02009;22.0</td><td>5.9&#x02009;&#x000b1;&#x02009;14.4</td><td>5.7&#x02009;&#x000b1;&#x02009;13.7</td><td>6.3&#x02009;&#x000b1;&#x02009;14.6</td><td>&#x02013;</td><td>0.96</td><td>0.50</td></tr><tr><td>IL-1RA (pg/ml)</td><td>33.1&#x02009;&#x000b1;&#x02009;26.2</td><td>27.8&#x02009;&#x000b1;&#x02009;18.6</td><td>26.3&#x02009;&#x000b1;&#x02009;16.0</td><td>60.6&#x02009;&#x000b1;&#x02009;66.6</td><td>77.2&#x02009;&#x000b1;&#x02009;77.2</td><td>78.8&#x02009;&#x000b1;&#x02009;105.8</td><td>&#x02013;</td><td>0.88</td><td>0.72</td></tr><tr><td>PGE2 (pg/ml)</td><td>496.5&#x02009;&#x000b1;&#x02009;452.7</td><td>636.4&#x02009;&#x000b1;&#x02009;544.9</td><td>353.0&#x02009;&#x000b1;&#x02009;357.5</td><td>605.1&#x02009;&#x000b1;&#x02009;491.2</td><td>605.6&#x02009;&#x000b1;&#x02009;504.6</td><td>661.7&#x02009;&#x000b1;&#x02009;503.7</td><td>0.07</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>LTB4 (pg/ml)</td><td>127.8&#x02009;&#x000b1;&#x02009;181.8</td><td>119.8&#x02009;&#x000b1;&#x02009;194.9</td><td>77.0&#x02009;&#x000b1;&#x02009;73.8</td><td>121.3&#x02009;&#x000b1;&#x02009;172.3</td><td>87.6&#x02009;&#x000b1;&#x02009;59.3</td><td>145.1&#x02009;&#x000b1;&#x02009;179.8</td><td>&#x02013;</td><td>0.70</td><td>0.78</td></tr></tbody></table><table-wrap-foot><p>All results are shown as mean&#x02009;&#x000b1;&#x02009;SD. <italic>p</italic> values correspond to group&#x02009;&#x000d7;&#x02009;time interactions, Mann-Whitney change scores, and Friedman scores for treatment group, respectively</p><p>Proinflammatory composite consists of a composite score averaging IL-2, IL-6, IL-1B, TNF-&#x003b1;, and IFN-y</p><p>Anti-inflammatory composite consists of a composite score averaging IL-4, IL-10, and IL1RA</p><p>*Significantly different from baseline with <italic>p</italic> value &#x0003c;0.05</p><p>**Significantly different from baseline with <italic>p</italic> value &#x0003c;0.01</p><p>Note: Adapted from &#x0201c;Targeting inflammation to influence mood following spinal cord injury: A randomized clinical trial&#x0201d; by David J. Allison and David S. Ditor, 2015, Journal of Neuroinflammation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Relationship between inflammatory mediators and indices of pain</title><p>Results from the multiple regression are shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. To help elucidate a potential mechanism between the reduction in neuropathic pain scores and inflammatory mediators, a stepwise backward multiple regression analysis was performed. When assessing the change in sensory pain score as the outcome variable, results from the regression analysis provided partial confirmation of the research hypothesis that change in sensory neuropathic pain is a function of the change in proinflammatory cytokines and eicosanoids. The three-variable model included the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (<italic>R</italic>&#x02009;=&#x02009;0.689, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.474). The overall <italic>F</italic> statistic for the model was 4.811, df&#x02009;=&#x02009;3.16, <italic>p</italic>&#x02009;=&#x02009;0.01. Standardized beta weights were &#x02212;0.730 for IL-2, 0.544 for IFN-y, and 0.526 for PGE2. When assessing the change in affective pain score as the outcome variable, only PGE2 remained in the model (<italic>R</italic>&#x02009;=&#x02009;0.558, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.312). The overall <italic>F</italic> statistic for the one-variable model was 8.145, df&#x02009;=&#x02009;1.18, <italic>p</italic>&#x02009;=&#x02009;0.01, and the standardized beta weight was 0.558. Lastly, when assessing the change in sensitivity score as the outcome variable, a three-variable model including the proinflammatory cytokines IL-1B and IL-2 as well as the eicosanoid PGE2 remained (<italic>R</italic>&#x02009;=&#x02009;0.715, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.511). The overall <italic>F</italic> statistic for the three-variable model was 5.580, df&#x02009;=&#x02009;3.16, <italic>p</italic>&#x02009;=&#x02009;0.008. Standardized beta weights were 0.491 for IL-1B, &#x02212;0.666 for IL-2, and 0.378 for PGE2.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Backward stepwise multiple regression analysis of the relationship between the change in neuropathic pain scores and the change in inflammatory mediators</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Outcome variable</th><th>Predictor variables</th><th>
<italic>b</italic>
</th><th>SE-b</th><th>Beta</th><th>
<italic>t</italic>
</th><th>
<italic>p</italic> value</th><th>Tolerance</th><th>VIF</th></tr></thead><tbody><tr><td>Sensory</td><td>IL-2</td><td>&#x02212;1.386</td><td>.483</td><td>&#x02212;0.73</td><td>&#x02212;2.87</td><td>0.01</td><td>0.51</td><td>1.97</td></tr><tr><td>(<italic>R</italic>&#x02009;=&#x02009;0.69, <italic>R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.47)</td><td>IFN-y</td><td>.179</td><td>.081</td><td>0.54</td><td>2.21</td><td>0.04</td><td>0.52</td><td>1.91</td></tr><tr><td/><td>PGE2</td><td>.022</td><td>.008</td><td>0.53</td><td>2.79</td><td>0.01</td><td>0.92</td><td>1.08</td></tr><tr><td>Affective</td><td>PGE2</td><td>.02</td><td>.01</td><td>0.56</td><td>2.85</td><td>0.01</td><td/><td/></tr><tr><td colspan="9">(<italic>R</italic>&#x02009;=&#x02009;0.56, <italic>R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.31)</td></tr><tr><td>Sensitivity</td><td>IL-1B</td><td>9.67</td><td>4.93</td><td>0.49</td><td>1.96</td><td>0.07</td><td>0.49</td><td>2.05</td></tr><tr><td>(<italic>R</italic>&#x02009;=&#x02009;0.72, <italic>R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.51)</td><td>IL-2</td><td>&#x02212;1.49</td><td>.49</td><td>&#x02212;0.67</td><td>&#x02212;3.07</td><td>0.01</td><td>0.65</td><td>1.54</td></tr><tr><td/><td>PGE2</td><td>.02</td><td>.01</td><td>0.38</td><td>1.8</td><td>0.09</td><td>0.69</td><td>1.45</td></tr></tbody></table></table-wrap></p><p>In order to account for the potential influence of depression on sensory neuropathic pain scores, an additional multiple regression analysis was performed while controlling for CES-D scores of depression. In this analysis, model 1 included CES-D scores of depression and model 2 included the inflammatory mediators IL-2, IFN-y, and PGE2. Model 1 resulted in a non-significant <italic>R</italic> square change score of 0.131 (<italic>p</italic>&#x02009;=&#x02009;0.12) while model 2 resulted in a significant <italic>R</italic> square change score of 0.394 (<italic>p</italic>&#x02009;=&#x02009;0.03). This suggests that the change in inflammatory mediators IL-2, IFN-y, and PGE2 explains an additional 39&#x000a0;% of the variability in the change in sensory neuropathic pain scores when the change in CES-D scores of depression has been statistically controlled for. When assessing standardized beta weights, CES-D scores were not significant (beta&#x02009;=&#x02009;0.244, <italic>p</italic>&#x02009;=&#x02009;0.23), while IL-2 and PGE2 remained significant (beta&#x02009;=&#x02009;&#x02212;0.731, <italic>p</italic>&#x02009;=&#x02009;0.01; beta&#x02009;=&#x02009;0.495, <italic>p</italic>&#x02009;=&#x02009;0.03, respectively), and IFN-y showed a trend towards significance (beta&#x02009;=&#x02009;0.462, <italic>p</italic>&#x02009;=&#x02009;0.07). The relationship between neuropathic pain scores and inflammatory mediators was also assessed at baseline by means of a stepwise backward elimination multiple regression analysis. When assessing baseline sensory neuropathic pain scores, IL-4 and PGE2 remained in the model (<italic>R</italic>&#x02009;=&#x02009;0.672, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.451). The overall <italic>F</italic> statistic for the model was 4.385, df&#x02009;=&#x02009;3.16, <italic>p</italic>&#x02009;=&#x02009;0.02. Standardized beta weights were &#x02212;0.783 and 0.472 for IL-4 and PGE2, respectively. When assessing baseline affective neuropathic pain scores, IL-2, IFN-y, PGE2, and IL-4 remained in the model (<italic>R</italic>&#x02009;=&#x02009;0.914, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.836). The overall <italic>F</italic> statistic for the model was 14.295, df&#x02009;=&#x02009;5.14, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01. Standardized beta weights were &#x02212;0.580 for IL-2, 0.756 for IFN-y, 0.965 for PGE2, and &#x02212;0.832 for IL-4. When assessing baseline sensitivity pain scores, IL-4 and LTB4 remained in the model (<italic>R</italic>&#x02009;=&#x02009;0.909, <italic>R</italic><sup>2</sup>&#x02009;=&#x02009;0.826). The overall <italic>F</italic> statistic for the model was 13.313, df&#x02009;=&#x02009;5.14, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01. Standardized beta weights were &#x02212;0.567 for IL-4 and 0.850 for LTB4.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>The present study successfully obtained reductions in inflammatory mediators and scores of sensory neuropathic pain in individuals with chronic SCI by means of dietary alterations. The relationship between changes in inflammatory mediators and changes in sensory neuropathic pain scores was assessed via a stepwise, backward elimination multiple regression analysis. It was demonstrated that approximately 47&#x000a0;% of the change in sensory neuropathic pain scores could be explained by the change in three inflammatory mediators including IL-2, IFN-y, and PGE2. Both IFN-y and PGE2 demonstrated positive relationships whereby a one-unit decrease in these mediators was related to a respective 0.544- and 0.526-unit decrease in sensory neuropathic pain scores. IL-2 demonstrated a negative relationship whereby a one-unit increase was related to a 0.730-unit decrease in sensory neuropathic pain scores. As changes in depression may also be expected to influence changes in neuropathic pain, an additional multiple regression analysis while controlling for CES-D scores of depression was conducted. This analysis showed that the inflammatory mediators IL-2, IFN-y, and PGE2 explained an additional 39&#x000a0;% of the change in sensory neuropathic pain scores even when controlling for the change in CES-D scores. The relationship between these inflammatory mediators and sensory neuropathic pain scores may be explained by the various peripheral and central mechanisms through which these mediators have been shown influence pain.</p><p>Under non-pathological conditions, free nerve endings in the periphery detect painful mechanical, thermal, or chemical stimuli and generate nerve impulses which then travel along afferent A-delta, or C fibers to the dorsal horn of the spinal cord. At this point, A-delta fibers synapse with second order neurons (while C fibers first synapse with interneurons) before ascending along the spinothalamic tract to the thalamus and somatosensory cortex whereby the magnitude and location of pain is processed. Under pathological conditions, chronic inflammation may influence pain signaling at different points along this pathway.</p><p>PGE2 has been shown to be a key factor in inflammatory-evoked pain by means of inducing sensitization of peripheral nociceptors as well as by inducing central changes concerning the processing of spinal nociceptive input [<xref ref-type="bibr" rid="CR16">16</xref>]. Peripherally, PGE2 acts on corresponding receptors (EP) on the nociceptor which causes a protein kinase A (PKA)-mediated phosphorylation of sodium channels thereby causing peripheral sensitization [<xref ref-type="bibr" rid="CR16">16</xref>]. PGE2 has also been shown to induce similar effects centrally by inducing membrane depolarization of dorsal horn neurons leading to action potential generation [<xref ref-type="bibr" rid="CR17">17</xref>]. There is also evidence that PGE2 may target the inhibitory glycine receptor thereby reducing inhibitory glycinergic synaptic transmission. This provides a second mechanism by which PGE2 may facilitate transmission of nociceptive input through the dorsal horn of the spinal cord [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>There is also evidence that LTB4 may act centrally to contribute to neuropathic pain. LTB4 can activate BLT1 (leukotriene B4 receptor 1) receptors, which are expressed on the membrane of spinal dorsal horn neurons during neuropathic pain [<xref ref-type="bibr" rid="CR19">19</xref>]. This activation induces the enhancement of NMDA currents via intracellular G-proteins. The enhancement of NMDA receptor sensitivity of dorsal horns may then contribute to central sensitization and pain hypersensitivity [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>IFN-y has also been shown to induce central effects which contribute to the enhancement of neuropathic pain. Spinal microglia express receptors for IFN-y. Once activated by IFN-y, they have been shown to induce the production of bioactive factors such as cytokines and neurotrophic factors [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] thereby influencing the excitability of the dorsal horn pathway [<xref ref-type="bibr" rid="CR22">22</xref>] and injury-induced pain behaviors [<xref ref-type="bibr" rid="CR23">23</xref>]. Through this process, IFN-y is able to indirectly enhance pain processing in the dorsal horn and influence neuropathic pain.</p><p>The negative relationship found between IL-2 and sensory pain scores can be explained by previous reports which have demonstrated antinociceptive properties of IL-2. Pain transmission can be depressed by means of inducing hyperpolarization, thereby reducing neuronal excitability, and depressing the release of nociceptive neurotransmitters [<xref ref-type="bibr" rid="CR24">24</xref>]. Free intracellular calcium (Ca<sup>2+</sup>) plays a key role in the release of nociceptive neurotransmitters such as substance P from the presynaptic neuron [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. It is through this mechanism that opioids have been demonstrated to produce their analgesic effects. The activation of opioid receptors has been shown to suppress high threshold Ca<sup>2+</sup> currents in rat dorsal root ganglion thereby inducing presynaptic inhibition [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. IL-2 administration has been demonstrated to induce a similar influence on high threshold Ca<sup>2+</sup> currents and inhibit the depolarization-evoked increase in intracellular Ca<sup>2+</sup> concentration [<xref ref-type="bibr" rid="CR29">29</xref>]. The fact that the administration of the u-opioid antagonist naloxone produces dramatic reductions in this effect suggests that IL-2 may also be producing these effects by acting on opioid receptors [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>Although speculative, the mechanisms discussed above may explain the link between the dietary-induced reduction in inflammation and the reductions in neuropathic pain scores observed in the current study. The fact that dietary alterations may target the underlying mechanisms of neuropathic pain may explain its effectiveness as a treatment modality. This could provide some advantage over traditional pharmacological treatments which focus on symptom relief aimed at downstream targets such as those involving the direct reduction of neuronal hyperexcitability. Such strategies have demonstrated mixed results in terms of efficacy, universality, and associated side effects. Examples include the use of tricyclic antidepressants which have shown efficacy for central pain [<xref ref-type="bibr" rid="CR31">31</xref>], but also a lack of effect for HIV neuropathy [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], or chemotherapy-induced neuropathic symptoms [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. SSRI&#x02019;s have also been shown to produce only weak analgesic effects (Sindrup et al., [<xref ref-type="bibr" rid="CR36">36</xref>]; Sindrup et al., [<xref ref-type="bibr" rid="CR37">37</xref>]; Otto et al., [<xref ref-type="bibr" rid="CR38">38</xref>]). The use of cannabinoids has been shown to relieve peripheral neuropathic pain in some studies (Karst M et al., [<xref ref-type="bibr" rid="CR39">39</xref>]; Nurmikko et al., [<xref ref-type="bibr" rid="CR40">40</xref>]; Baron et al., [<xref ref-type="bibr" rid="CR41">41</xref>]) but has shown no effect in painful poly-neuropathy [<xref ref-type="bibr" rid="CR42">42</xref>]. Anticonvulsants such as gabapentin have been shown to be effective for the relief of painful polyneuropathy [<xref ref-type="bibr" rid="CR43">43</xref>] but have also demonstrated a lack of effect in several studies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. Finally, opioids have been demonstrated, fairly consistently to benefit symptoms of neuropathic pain [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]; however, the risk of addiction and gastrointestinal side effects may make long-term use inappropriate [<xref ref-type="bibr" rid="CR52">52</xref>]. The fact that the etiological basis of neuropathic pain may be highly variable from one individual to another makes it difficult to establish a universally effective treatment and may explain the marginal effectiveness of many drug trials. While a particular drug treatment may demonstrate a large effect on a small subgroup of participants, it also commonly shows a complete lack of effect in others, resulting in minimal overall efficacy. As dietary alterations are capable of targeting the underlying inflammatory mechanisms of neuropathic pain, they may provide a more widely applicable treatment option.</p><p>In addition to the potential for a greater universality and reduction in undesirable side-effects, anti-inflammatory strategies such as that utilized in the current study, may provide benefits comparable in magnitude to traditional pharmacological methods. Gabapentin is currently among the most promising pharmaceutical treatments for neuropathic pain. Studies which examined an 8-week administration of gabapentin have demonstrated reductions in neuropathic pain scores of 40.6&#x000a0;% in individuals with painful diabetic neuropathy [<xref ref-type="bibr" rid="CR53">53</xref>], 33.3&#x000a0;% in individuals with postherpetic neuralgia [<xref ref-type="bibr" rid="CR54">54</xref>], and 21.1&#x000a0;% in individuals with mixed neuropathic pain syndromes [<xref ref-type="bibr" rid="CR55">55</xref>] (based on an 11-point Likert scale). The 39.6&#x000a0;% reduction in sensory neuropathic pain scores achieved in the current study is therefore of comparable or better magnitude to that achieved following gabapentin administration. Further, according to Farrar et al. [<xref ref-type="bibr" rid="CR56">56</xref>], a 30&#x000a0;% reduction in a pain intensity numerical rating scale (PI-NRS) represents a clinically important difference in pain [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>It has also been suggested that the TH1:TH2 balance may play a role in the severity of neuropathic pain. Studies related to painful neuropathy following SCI have shown elevated levels of the proinflammatory cytokines TNF, IL-6, and IL-2, combined with reduced concentrations of the anti-inflammatory cytokines IL-10 and IL-4 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Alternatively, individuals with painless neuropathies have been shown to have elevated levels of anti-inflammatory cytokines [<xref ref-type="bibr" rid="CR15">15</xref>]. It may therefore be possible that improvements in neuropathic pain in the current study would have been even more substantial had anti-inflammatory cytokines been successfully increased.</p><p>Several potential study limitations should be noted. First, the study was only single blinded. While the examiner was blinded to group allocation during all blood analysis, participants were aware of their group assignment. Although placebo supplements could have been provided to the control group, it was not possible to adequately blind participants to all aspects of the diet. The treatment group underwent a highly restrictive diet devoid of any refined, processed, or fried foods while the control group was free to consume such foods, making distinction between groups quite obvious. For this reason, the potential for a placebo effect to have influenced the changes in neuropathic pain to some extent cannot be ignored. A recent review by Cragg et al. [<xref ref-type="bibr" rid="CR58">58</xref>] concluded that on average, a weak yet statistically significant placebo response was apparent in individuals with central neuropathic pain [<xref ref-type="bibr" rid="CR58">58</xref>]. Second, it is not possible to elucidate the specific mechanisms related to the reductions in inflammation, nor is it possible to discern which aspects of the dietary intervention may have had the strongest effects. It will be necessary for future studies to examine aspects such as transcription factor activity and membrane composition in order to truly elucidate the means by which such interventions act to reduce inflammation and improve symptoms of neuropathic pain. Third, although our sample was quite representative of the SCI population in Canada, in terms of age, level, and severity of injury [<xref ref-type="bibr" rid="CR59">59</xref>], the results are not necessarily generalizable to other chronic inflammatory populations or all forms of neuropathic pain. It is also worth noting that the use of interventions which target inflammation by such means as diet or exercise requires commitment to major lifestyle alterations and it may be possible that improvements are less drastic and occur at a slower rate than that of certain pharmaceuticals. However, given the potential for such anti-inflammatory interventions to provide a more widely applicable aid for neuropathic pain symptoms (in addition to contributing to a multitude of other health benefits), while lacking the side effects associated with traditional pain medications, there is seemingly little reason not to promote such lifestyle alterations as a treatment option.</p></sec><sec id="Sec14" sec-type="conclusion"><title>Conclusions</title><p>The present study demonstrated that it was possible to improve symptoms of neuropathic pain in spinal cord injury by means by reducing levels of inflammation. Secondarily, appropriate dietary alterations may be one such intervention strategy which could be used to reduce inflammation and induce such benefits. This influence is worthy of further examination as it may help to reduce the reliance on traditional pain medications and provide a safe, sustainable, and more widely applicable treatment modality.</p></sec><sec id="Sec15"><title>Abbreviations</title><p>Ca<sup>2+</sup>, calcium; CRP, C-reactive protein; IFN-y, interferon gamma; IL, interleukin; LTB4, leukotriene B4; NPQ, neuropathic pain questionnaire; PGE2, prostaglandin E2; SCI, spinal cord injury; SSRI, selective serotonin reuptake inhibitor; TNF-&#x003b1;, tumor necrosis factor alpha</p></sec></body><back><app-group><app id="App1"><sec id="Sec16"><title>Additional files</title><p><media position="anchor" xlink:href="12974_2016_625_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1:</label><caption><p>CONSORT 2010 Flow Diagram. (DOC 52 kb)</p></caption></media><media position="anchor" xlink:href="12974_2016_625_MOESM2_ESM.docx" id="MOESM2"><label>Additional file 2:</label><caption><p>Raw Data. (DOCX 56 kb)</p></caption></media></p></sec></app></app-group><ack><title>Acknowledgements</title><p>This study was supported by the Ontario Neurotrauma Foundation. We wish to thank Now, CanPrev, AOR, and Progressive for providing the supplements utilized in the dietary intervention. We also wish to thank Dr. Philip Sullivan for his assistance with the statistical analysis.</p><sec id="FPar1"><title>Funding</title><p>This study was supported by the Ontario Neurotrauma Foundation.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets supporting the conclusions of this article are included within the article and in Additional files <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>DJA was responsible for the conceptualization of the project, data collection, data analysis, and manuscript preparation. AT and KB were responsible for assisting in the data collection and data analysis. DSD assisted in the conceptualization of the project, data analysis, and manuscript preparation. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The study received ethical approval from the Brock University Research Ethics Board as well as the Natural Health Products Directorate of Canada.</p><p>Informed consent was obtained from all participants.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Hehn</surname><given-names>CA</given-names></name><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Deconstructing the neuropathic pain phenotype to reveal neural mechanisms</article-title><source>Neuron</source><year>2012</year><volume>73</volume><fpage>638</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.02.008</pub-id><pub-id pub-id-type="pmid">22365541</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddall</surname><given-names>PJ</given-names></name><name><surname>Mcclelland</surname><given-names>JM</given-names></name><name><surname>Rutkowski</surname><given-names>SB</given-names></name><name><surname>Cousins</surname><given-names>MJ</given-names></name></person-group><article-title>A longitudinal study of the prevalence and characteristics of pain in the first 5&#x000a0;years following spinal cord injury</article-title><source>Pain</source><year>2003</year><volume>103</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00452-9</pub-id><pub-id pub-id-type="pmid">12791431</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widerstrom-Noga</surname><given-names>EG</given-names></name><name><surname>Felipe-Cuervo</surname><given-names>E</given-names></name><name><surname>Yezierski</surname><given-names>RP</given-names></name></person-group><article-title>Chronic pain after spinal injury: Interference with sleep and daily activities</article-title><source>Arch Phys Med Rehabil</source><year>2001</year><volume>82</volume><fpage>1571</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1053/apmr.2001.26068</pub-id><pub-id pub-id-type="pmid">11689978</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Sindrup</surname><given-names>SH</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name></person-group><article-title>The evidence for pharmacological treatment of neuropathic pain</article-title><source>Pain</source><year>2010</year><volume>150</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2010.06.019</pub-id><pub-id pub-id-type="pmid">20705215</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>CJ</given-names></name><name><surname>Mannion</surname><given-names>RJ</given-names></name></person-group><article-title>Neuropathic pain: aetiology, symptoms, mechanisms, and management</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1959</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)01307-0</pub-id><pub-id pub-id-type="pmid">10371588</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>C</given-names></name><name><surname>Kress</surname><given-names>M</given-names></name></person-group><article-title>Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia</article-title><source>Neurosci Lett</source><year>2004</year><volume>361</volume><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2003.12.007</pub-id><pub-id pub-id-type="pmid">15135924</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitchford</surname><given-names>S</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name></person-group><article-title>Prostaglandins sensitize nociceptors in cell culture</article-title><source>Neurosci Lett</source><year>1991</year><volume>132</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(91)90444-X</pub-id><pub-id pub-id-type="pmid">1724065</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>CJ</given-names></name><name><surname>Allchorne</surname><given-names>A</given-names></name><name><surname>Safieh-Garabedian</surname><given-names>B</given-names></name><name><surname>Poole</surname><given-names>S</given-names></name></person-group><article-title>Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha</article-title><source>Br J Pharmacol</source><year>1997</year><volume>121</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0701148</pub-id><pub-id pub-id-type="pmid">9179382</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honore</surname><given-names>P</given-names></name><name><surname>Wade</surname><given-names>CL</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>RR</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Ghayur</surname><given-names>T</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Decker</surname><given-names>MW</given-names></name><name><surname>Faltynek</surname><given-names>C</given-names></name><name><surname>Sullivan</surname><given-names>J</given-names></name><name><surname>Jarvis</surname><given-names>MF</given-names></name></person-group><article-title>Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain</article-title><source>Behav Brain Res</source><year>2006</year><volume>167</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2005.09.024</pub-id><pub-id pub-id-type="pmid">16256210</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name><name><surname>Gabay</surname><given-names>E</given-names></name><name><surname>Tal</surname><given-names>M</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name><name><surname>Shavit</surname><given-names>Y</given-names></name></person-group><article-title>Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice</article-title><source>Pain</source><year>2006</year><volume>120</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2005.11.011</pub-id><pub-id pub-id-type="pmid">16426759</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>PC</given-names></name></person-group><article-title>Omega-3 fatty acids and inflammatory processes</article-title><source>Nutrients</source><year>2010</year><volume>2</volume><fpage>355</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.3390/nu2030355</pub-id><pub-id pub-id-type="pmid">22254027</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>AL</given-names></name><name><surname>Hayes</surname><given-names>KC</given-names></name><name><surname>Dekaban</surname><given-names>GA</given-names></name></person-group><article-title>Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury</article-title><source>Arch Phys Med Rehabil</source><year>2007</year><volume>88</volume><fpage>1384</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2007.08.004</pub-id><pub-id pub-id-type="pmid">17964877</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>KC</given-names></name><name><surname>Hull</surname><given-names>TCL</given-names></name><name><surname>Delaney</surname><given-names>GA</given-names></name><name><surname>Potter</surname><given-names>PJ</given-names></name><name><surname>Sequeira</surname><given-names>KAJ</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Popovich</surname><given-names>PG</given-names></name></person-group><article-title>Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury</article-title><source>J Neurotrauma</source><year>2002</year><volume>19</volume><fpage>753</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1089/08977150260139129</pub-id><pub-id pub-id-type="pmid">12165135</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>DJ</given-names></name><name><surname>Ditor</surname><given-names>DS</given-names></name></person-group><article-title>Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial</article-title><source>J Neuroinflammation</source><year>2015</year><volume>12</volume><fpage>204</fpage><pub-id pub-id-type="doi">10.1186/s12974-015-0425-2</pub-id><pub-id pub-id-type="pmid">26545369</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>U&#x000e7;eyler</surname><given-names>N</given-names></name><name><surname>Rogausch</surname><given-names>JP</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name><name><surname>Sommer</surname><given-names>C</given-names></name></person-group><article-title>Differential expression of cytokines in painful and painless neuropathies</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000265062.92340.a5</pub-id><pub-id pub-id-type="pmid">17606879</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samad</surname><given-names>TA</given-names></name><name><surname>Sapirstein</surname><given-names>A</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets</article-title><source>Trends Mol Med</source><year>2002</year><volume>8</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/S1471-4914(02)02383-3</pub-id><pub-id pub-id-type="pmid">12127725</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>KA</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><article-title>Direct activation of rat spinal dorsal horn neurons by prostaglandin E2</article-title><source>J Neurosci</source><year>2001</year><volume>21</volume><fpage>1750</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">11222664</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>S</given-names></name><name><surname>Lippross</surname><given-names>S</given-names></name><name><surname>Neuhuber</surname><given-names>WL</given-names></name><name><surname>Zeilhofer</surname><given-names>HU</given-names></name></person-group><article-title>PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons</article-title><source>Nat Neurosci</source><year>2002</year><volume>5</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nn778</pub-id><pub-id pub-id-type="pmid">11740501</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyoyuki</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>W</given-names></name><name><surname>Okubo</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Nishio</surname><given-names>N</given-names></name><name><surname>Nakatsuka</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name></person-group><article-title>Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury</article-title><source>Mol Pain</source><year>2015</year><volume>11</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12990-015-0059-5</pub-id><pub-id pub-id-type="pmid">26353783</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><article-title>The function of microglia through purinergic receptors: neuropathic pain and cytokine release</article-title><source>Pharmacol Ther</source><year>2006</year><volume>109</volume><fpage>210</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2005.07.001</pub-id><pub-id pub-id-type="pmid">16169595</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000e4;rber</surname><given-names>K</given-names></name><name><surname>Kettenmann</surname><given-names>H</given-names></name></person-group><article-title>Purinergic signaling and microglia</article-title><source>Pflugers Arch Eur J Physiol</source><year>2006</year><volume>452</volume><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1007/s00424-006-0064-7</pub-id><pub-id pub-id-type="pmid">16791619</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>AF</given-names></name><name><surname>Beggs</surname><given-names>S</given-names></name><name><surname>Salter</surname><given-names>MW</given-names></name><name><surname>De Koninck</surname><given-names>Y</given-names></name></person-group><article-title>Transformation of the output of spinal lamina I neurons after nerve injury and microglia stimulation underlying neuropathic pain</article-title><source>Mol Pain</source><year>2007</year><volume>3</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/1744-8069-3-27</pub-id><pub-id pub-id-type="pmid">17207285</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>J</given-names></name><name><surname>Shimoyama</surname><given-names>H</given-names></name><name><surname>Tozaki-Saitoh</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><article-title>IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>8032</fpage><lpage>8037</lpage><pub-id pub-id-type="doi">10.1073/pnas.0810420106</pub-id><pub-id pub-id-type="pmid">19380717</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipp</surname><given-names>J</given-names></name></person-group><article-title>Possible mechanisms of morphine analgesia</article-title><source>Clin Neuropharmacol</source><year>1991</year><volume>14</volume><fpage>131</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1097/00002826-199104000-00003</pub-id><pub-id pub-id-type="pmid">1849794</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>BJ</given-names></name><name><surname>Rogers</surname><given-names>SD</given-names></name><name><surname>Ghilardi</surname><given-names>JR</given-names></name><name><surname>Menning</surname><given-names>PM</given-names></name><name><surname>Kuskowski</surname><given-names>MA</given-names></name><name><surname>Basbaum</surname><given-names>AI</given-names></name><name><surname>Simone</surname><given-names>DA</given-names></name><name><surname>Mantyh</surname><given-names>PW</given-names></name></person-group><article-title>Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo</article-title><source>J Neurosci</source><year>1997</year><volume>17</volume><fpage>5921</fpage><lpage>5927</lpage><pub-id pub-id-type="pmid">9221788</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakanishi</surname><given-names>S</given-names></name></person-group><article-title>Mammalian tachykinin receptors</article-title><source>Annu Rev Neurosci</source><year>1991</year><volume>14</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1146/annurev.ne.14.030191.001011</pub-id><pub-id pub-id-type="pmid">1851606</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>JE</given-names></name><name><surname>Fischbach</surname><given-names>PS</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Mccleskey</surname><given-names>EW</given-names></name></person-group><article-title>Activation of u opioid receptors inhibits transient high- and low-threshold Ca2+ currents, but spares a sustained current</article-title><source>Cell</source><year>1991</year><volume>6</volume><fpage>13</fpage><lpage>20</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moises</surname><given-names>HC</given-names></name><name><surname>Rusin</surname><given-names>KI</given-names></name><name><surname>Macdonald</surname><given-names>RL</given-names></name></person-group><article-title>Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons</article-title><source>J Neurosci</source><year>1994</year><volume>14</volume><fpage>5903</fpage><lpage>5916</lpage><pub-id pub-id-type="pmid">7931552</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>P</given-names></name></person-group><article-title>Interleukin-2 regulates membrane potentials and calcium channels via &#x003bc; opioid receptors in rat dorsal root ganglion neurons</article-title><source>Neuropharmacology</source><year>2002</year><volume>43</volume><fpage>1324</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(02)00298-8</pub-id><pub-id pub-id-type="pmid">12527482</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Interleukin 2-induced antinociception partially coupled with mu receptor</article-title><source>Cytokine+</source><year>2000</year><volume>12</volume><fpage>1240</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">10930304</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rintala</surname><given-names>DH</given-names></name><name><surname>Holmes</surname><given-names>SA</given-names></name><name><surname>Courtade</surname><given-names>D</given-names></name><name><surname>Fiess</surname><given-names>RN</given-names></name><name><surname>Tastard</surname><given-names>LV</given-names></name><name><surname>Loubser</surname><given-names>PG</given-names></name></person-group><article-title>Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury</article-title><source>Arch Phys Med Rehabil</source><year>2007</year><volume>88</volume><fpage>1547</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2007.07.038</pub-id><pub-id pub-id-type="pmid">18047869</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Yiannoutsos</surname><given-names>C</given-names></name><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Hall</surname><given-names>CD</given-names></name><name><surname>Ellis</surname><given-names>RJ</given-names></name><name><surname>Marra</surname><given-names>CM</given-names></name><name><surname>McKendall</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>E</given-names></name><name><surname>Dal Pan</surname><given-names>GJ</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Tucker</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>B</given-names></name></person-group><article-title>A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>1682</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1212/WNL.51.6.1682</pub-id><pub-id pub-id-type="pmid">9855523</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlay</surname><given-names>JC</given-names></name><name><surname>Chaloner</surname><given-names>K</given-names></name><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Flaws</surname><given-names>B</given-names></name><name><surname>Reichelderfer</surname><given-names>P</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name><name><surname>Hillman</surname><given-names>S</given-names></name><name><surname>Brizz</surname><given-names>B</given-names></name><name><surname>Cohn</surname><given-names>DL</given-names></name></person-group><article-title>Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>1590</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1001/jama.280.18.1590</pub-id><pub-id pub-id-type="pmid">9820261</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammack</surname><given-names>JE</given-names></name><name><surname>Michalak</surname><given-names>JC</given-names></name><name><surname>Loprinzi</surname><given-names>CL</given-names></name><name><surname>Sloan</surname><given-names>JA</given-names></name><name><surname>Novotny</surname><given-names>PJ</given-names></name><name><surname>Soori</surname><given-names>GS</given-names></name><name><surname>Tirona</surname><given-names>MT</given-names></name><name><surname>Rowland</surname><given-names>KM</given-names></name><name><surname>Stella</surname><given-names>PJ</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy</article-title><source>Pain</source><year>2002</year><volume>98</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00047-7</pub-id><pub-id pub-id-type="pmid">12098632</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautio</surname><given-names>A-L</given-names></name><name><surname>Haanp&#x000e4;&#x000e4;</surname><given-names>M</given-names></name><name><surname>Saarto</surname><given-names>T</given-names></name><name><surname>Kalso</surname><given-names>E</given-names></name></person-group><article-title>Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms</article-title><source>J Pain Symptom Manage</source><year>2008</year><volume>35</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2007.02.043</pub-id><pub-id pub-id-type="pmid">17980550</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindrup</surname><given-names>SH</given-names></name><name><surname>Gram</surname><given-names>LF</given-names></name><name><surname>Brersen</surname><given-names>K</given-names></name><name><surname>Eshcij</surname><given-names>O</given-names></name><name><surname>Mogensen</surname><given-names>EF</given-names></name></person-group><article-title>The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms</article-title><source>Pain</source><year>1990</year><volume>42</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(90)91157-E</pub-id><pub-id pub-id-type="pmid">2147235</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindrup</surname><given-names>SH</given-names></name><name><surname>Bjerre</surname><given-names>U</given-names></name><name><surname>Dejgaard</surname><given-names>A</given-names></name><name><surname>Br&#x000f8;sen</surname><given-names>K</given-names></name><name><surname>Aaes-J&#x000f8;rgensen</surname><given-names>TGL</given-names></name></person-group><article-title>The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>52</volume><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/clpt.1992.183</pub-id><pub-id pub-id-type="pmid">1424428</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Bach</surname><given-names>FW</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Br&#x000f8;sen</surname><given-names>K</given-names></name><name><surname>Sindrup</surname><given-names>SH</given-names></name></person-group><article-title>Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial</article-title><source>Pain</source><year>2008</year><volume>139</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2008.04.012</pub-id><pub-id pub-id-type="pmid">18547727</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karst</surname><given-names>M</given-names></name><name><surname>Salim</surname><given-names>K</given-names></name><name><surname>Burstein</surname><given-names>S</given-names></name><name><surname>Conrad</surname><given-names>I</given-names></name><name><surname>Hoy</surname><given-names>LSU</given-names></name></person-group><article-title>Analgesic effect of the synthetic cannabinoid</article-title><source>J Am Med Assoc</source><year>2003</year><volume>290</volume><fpage>1757</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1001/jama.290.13.1757</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurmikko</surname><given-names>TJ</given-names></name><name><surname>Serpell</surname><given-names>MG</given-names></name><name><surname>Hoggart</surname><given-names>B</given-names></name><name><surname>Toomey</surname><given-names>PJ</given-names></name><name><surname>Morlion</surname><given-names>BJ</given-names></name><name><surname>Haines</surname><given-names>D</given-names></name></person-group><article-title>Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial</article-title><source>Pain</source><year>2007</year><volume>133</volume><fpage>210</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2007.08.028</pub-id><pub-id pub-id-type="pmid">17997224</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Mayoral</surname><given-names>V</given-names></name><name><surname>Leijon</surname><given-names>G</given-names></name><name><surname>Binder</surname><given-names>A</given-names></name><name><surname>Steigerwald</surname><given-names>I</given-names></name><name><surname>Serpell</surname><given-names>M</given-names></name></person-group><article-title>5&#x000a0;% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study</article-title><source>Curr Med Res Opin</source><year>2009</year><volume>25</volume><fpage>1663</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1185/03007990903047880</pub-id><pub-id pub-id-type="pmid">19485723</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvarajah</surname><given-names>D</given-names></name><name><surname>Gandhi</surname><given-names>R</given-names></name></person-group><article-title>Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>128</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.2337/dc09-1029</pub-id><pub-id pub-id-type="pmid">19808912</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandercock</surname><given-names>D</given-names></name><name><surname>Cramer</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chiang</surname><given-names>Y-K</given-names></name><name><surname>Biton</surname><given-names>V</given-names></name><name><surname>Heritier</surname><given-names>M</given-names></name></person-group><article-title>Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>e20</fpage><pub-id pub-id-type="doi">10.2337/dc08-1450</pub-id><pub-id pub-id-type="pmid">19171730</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordh</surname><given-names>TE</given-names></name><name><surname>Stubhaug</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Arn&#x000e8;r</surname><given-names>S</given-names></name><name><surname>Biber</surname><given-names>B</given-names></name><name><surname>Boivie</surname><given-names>J</given-names></name><name><surname>Mannheimer</surname><given-names>C</given-names></name><name><surname>Kalliom&#x000e4;ki</surname><given-names>J</given-names></name><name><surname>Kalso</surname><given-names>E</given-names></name></person-group><article-title>Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study</article-title><source>Pain</source><year>2008</year><volume>138</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2007.12.011</pub-id><pub-id pub-id-type="pmid">18258368</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>RD</given-names></name><name><surname>Michalak</surname><given-names>JC</given-names></name><name><surname>Sloan</surname><given-names>JA</given-names></name><name><surname>Loprinzi</surname><given-names>CL</given-names></name><name><surname>Soori</surname><given-names>GS</given-names></name><name><surname>Nikcevich</surname><given-names>DA</given-names></name><name><surname>Warner</surname><given-names>DO</given-names></name><name><surname>Novotny</surname><given-names>P</given-names></name><name><surname>Kutteh</surname><given-names>LA</given-names></name><name><surname>Wong</surname><given-names>GY</given-names></name></person-group><article-title>Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)</article-title><source>Cancer</source><year>2007</year><volume>110</volume><fpage>2110</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1002/cncr.23008</pub-id><pub-id pub-id-type="pmid">17853395</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Ehde</surname><given-names>DM</given-names></name><name><surname>Hanley</surname><given-names>MA</given-names></name><name><surname>Campbell</surname><given-names>KM</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Hoffman</surname><given-names>AJ</given-names></name><name><surname>Awan</surname><given-names>AB</given-names></name><name><surname>Czerniecki</surname><given-names>JM</given-names></name><name><surname>Robinson</surname><given-names>LR</given-names></name></person-group><article-title>Efficacy of gabapentin in treating chronic phantom limb and residual limb pain</article-title><source>J Rehabil Res Dev</source><year>2005</year><volume>42</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1682/JRRD.2005.05.0082</pub-id><pub-id pub-id-type="pmid">16586190</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Sindrup</surname><given-names>SH</given-names></name></person-group><article-title>Algorithm for neuropathic pain treatment: an evidence based proposal</article-title><source>Pain</source><year>2005</year><volume>118</volume><fpage>289</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2005.08.013</pub-id><pub-id pub-id-type="pmid">16213659</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name><name><surname>Hewitt</surname><given-names>DJ</given-names></name><name><surname>Vorsanger</surname><given-names>GJ</given-names></name><name><surname>Jordan</surname><given-names>DM</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Rosenthal</surname><given-names>NR</given-names></name></person-group><article-title>Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1185/030079906X162674</pub-id><pub-id pub-id-type="pmid">17257476</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>MC</given-names></name></person-group><article-title>Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients</article-title><source>Eur J Pain</source><year>2008</year><volume>12</volume><fpage>804</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2007.12.010</pub-id><pub-id pub-id-type="pmid">18262450</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilder-Smith</surname><given-names>CH</given-names></name><name><surname>Hill</surname><given-names>LT</given-names></name><name><surname>Hons</surname><given-names>BS</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name></person-group><article-title>Postamputation pain and sensory changes in treatment-naive patients</article-title><source>Anesthesiology</source><year>2005</year><volume>103</volume><fpage>619</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1097/00000542-200509000-00027</pub-id><pub-id pub-id-type="pmid">16129989</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Tella</surname><given-names>PK</given-names></name><name><surname>Klick</surname><given-names>B</given-names></name><name><surname>Clark</surname><given-names>MR</given-names></name><name><surname>Haythornthwaite</surname><given-names>JA</given-names></name><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name></person-group><article-title>Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31817f4523</pub-id><pub-id pub-id-type="pmid">18648238</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Webster</surname><given-names>LR</given-names></name><name><surname>Davies</surname><given-names>AN</given-names></name><name><surname>Mawe</surname><given-names>GM</given-names></name></person-group><article-title>Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation</article-title><source>Neurogastroenterol Motil</source><year>2014</year><volume>26</volume><fpage>1386</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1111/nmo.12417</pub-id><pub-id pub-id-type="pmid">25164154</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backonja</surname><given-names>M</given-names></name><name><surname>Beydoun</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>KR</given-names></name><name><surname>Schwartz</surname><given-names>SL</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Hes</surname><given-names>M</given-names></name><name><surname>La</surname><given-names>ML</given-names></name><name><surname>Garofalo</surname><given-names>E</given-names></name></person-group><article-title>Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial</article-title><source>Surv Anesthesiol</source><year>1999</year><volume>43</volume><fpage>236</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1097/00132586-199908000-00055</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serpell</surname><given-names>MG</given-names></name><name><surname>Pain</surname><given-names>N</given-names></name><name><surname>Group</surname><given-names>S</given-names></name></person-group><article-title>Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial</article-title><source>Pain</source><year>2002</year><volume>99</volume><issue>March 2000</issue><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(02)00255-5</pub-id><pub-id pub-id-type="pmid">12406532</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname><given-names>M</given-names></name><name><surname>Harden</surname><given-names>N</given-names></name><name><surname>Stacey</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>P</given-names></name><name><surname>Magnus-Miller</surname><given-names>L</given-names></name></person-group><article-title>Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>1837</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1001/jama.280.21.1837</pub-id><pub-id pub-id-type="pmid">9846778</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Young</surname><given-names>JP</given-names></name><name><surname>LaMoreaux</surname><given-names>L</given-names></name><name><surname>Werth</surname><given-names>JL</given-names></name><name><surname>Poole</surname><given-names>RM</given-names></name></person-group><article-title>Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale</article-title><source>Pain</source><year>2001</year><volume>94</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(01)00349-9</pub-id><pub-id pub-id-type="pmid">11690728</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>U&#x000e7;eyler</surname><given-names>N</given-names></name><name><surname>Eberle</surname><given-names>T</given-names></name><name><surname>Rolke</surname><given-names>R</given-names></name><name><surname>Birklein</surname><given-names>F</given-names></name><name><surname>Sommer</surname><given-names>C</given-names></name></person-group><article-title>Differential expression patterns of cytokines in complex regional pain syndrome</article-title><source>Pain</source><year>2007</year><volume>132</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2007.07.031</pub-id><pub-id pub-id-type="pmid">17890011</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>JJ</given-names></name><name><surname>Warner</surname><given-names>FM</given-names></name><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Mercier</surname><given-names>C</given-names></name><name><surname>Richards</surname><given-names>JS</given-names></name><name><surname>Wrigley</surname><given-names>P</given-names></name><name><surname>Soler</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>JL</given-names></name></person-group><article-title>Meta-analysis of placebo responses in central neuropathic pain</article-title><source>Pain</source><year>2016</year><volume>157</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000431</pub-id><pub-id pub-id-type="pmid">26447708</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noonan</surname><given-names>VK</given-names></name><name><surname>Fingas</surname><given-names>M</given-names></name><name><surname>Farry</surname><given-names>A</given-names></name><name><surname>Baxter</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Fehlings</surname><given-names>MG</given-names></name><name><surname>Dvorak</surname><given-names>MF</given-names></name></person-group><article-title>Incidence and prevalence of spinal cord injury in Canada: a national perspective</article-title><source>Neuroepidemiology</source><year>2012</year><volume>38</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1159/000336014</pub-id><pub-id pub-id-type="pmid">22555590</pub-id></element-citation></ref></ref-list></back></article>